Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAP-1502 Spray for Adult Scalp Psoriasis
CTR20260312Phase 3Active
- Sponsor
- Zedman Pharma
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing TAP-1502 Spray with Vehicle (placebo) Spray (2 arms). Primary endpoint: Scalp Physician Global Assessment (PGA) response rate at Day 84. Started Jan 2026; status: active.
02
Drugs
TAP-1502
03
Conditions
psoriasis
Beyond the preview
Go deeper on CTR20260312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260312.